March 5, 2018 Dr. Perlman's Latest Updates for John Paul Jr.
The UCLA Huntington’s Disease Center of Excellence continues to be the largest clinical research center for Huntington’s Disease west of the Mississippi River. Under the leadership of Susan Perlman, M.D., they provide consultation, clinical care, and clinical research opportunities to over 200 patients and families living with HD. They continue to collaborate with an international research consortium for HD in the investigation of the natural history of HD and in the development of new biomarkers to track disease progression and improvement. They have worked with a national consortium on better ways to support the caregivers. This past year, they completed two trials of new drugs for HD and are now in the middle of a third trial. The basic research lab is exploring a new possible disease modifying drug. They are currently working with two companies that have neuroprotective drugs that could be tried in HD. They are on the threshold of trials for drugs that could block the HD gene and make HD a treatable disease.
Dr. Perlman and her team cannot thank John Paul, Jr., enough for his advocacy on behalf of the HD community. John is an incredible person who inspired a movement worldwide to raise awareness and funds for Huntington’s disease research.
We are Involved in two new clinical drug trials that are translating new drug development into human use
• Two additional clinical drug trials to launch later this summer which will again involve application new drugs to HD patients
• In negotiations for two additional clinical drug trials of novel new drugs that might be neuroprotective
• Continuing to collaborate with a national research consortium for HD in the investigation of the natural history of HD and in the development of new biomarkers to track disease progression and improvement
501 c-3 at Last 6-15-14
TEAM JLP-HD is excited that after 18 months we have finally achieved our official status as a not for profit 501 c 3 corporation. Any contributions made during that time period are tax deductible as are all future donations. This alows us to seriously pursue fund raising efforts to stop the advancement of the symptoms of HD and find a cure. Thank you to everyone that has helped us along the way, expecially our friends in Atlanta, Vero Beach, and UCLA . We look forward to more successful efforts and events.
SEBRING 2013 HSR FINALE BENEFITS UCLA HUNTINGTON'S DISEASE RESEARCH
IN HONOR OF JOHN PAUL JR. DECEMBER-2013
The Department of Neurology, David Geffen School of Medicine at UCLA sincerely thanks the drivers, fans, and volunteers at the HSR event who came together in support of Huntington’s disease (HD) research. More than $30,000 in gifts (and counting) have been made to the John Paul Jr. Huntington Disease Fund.
Drs. Susan Perlman and Yvette Bordelon are leading the way in HD research in the Department of Neurology.
HD research progress:
Beginning two new clinical drug trials that are translating new drug development into human use
Preparing a third clinical drug trial to launch this the spring which will again involve application of a new drug to HD patients
In negotiations for a fourth clinical drug trial of a novel new drug that might be neuroprotective
Continuing to collaborate with a national research consortium for HD in the investigation of the natural history of HD and in the development of new biomarkers to track disease progression and improvement
Thank you for helping us “drive” our research forward in the race to find better answers for HD patients and their families.
Historic SportsCar Racing offers fans a chance to watch classic cars compete at Sebring International Raceway today and Sunday.
Special to Highlands Today
Published: December 7, 2013
Seven champion race-car drivers and one rock star racer will compete in a Porsche 935 JLP HD1 on Sunday to help raise funds and awareness for Huntington's Disease.
The 4-hour endurance event at the famed 3.7-mile Sebring International Speedway is sanctioned by Historic Sportscar Racing Ltd.
The race has internationally-acclaimed drivers Rob Dyson, John Fergus, Hurley Haywood, Roger Mandeville, Jim Pace, Brian Redman and Dorsey Schroeder.
Fans and supporters around the world are encouraged to visit (go to "Please Direct My Fund to..." and scroll down to "John Paul Jr.") where donations will be accepted in the name of the event and former racing champion John Paul Jr., who suffers from the disease.
John Paul Jr. is the youngest champion in IMSA GT Series history, and has won races at the 24 Hours of Daytona, in CART and the IRL.
In 1982, at age 22, he became the youngest winner of the prestigious 12 Hours of Sebring. Other former race drivers are known to suffer from Parkinson's, Multiple Sclerosis and Alzheimer's - all related to Huntington's. Paul Jr. is expected to join the Saturday evening reception through a Skype hook-up, along with other West Coast-based race-car drivers lending their support.
"This is such a debilitating disease, which has taken its toll on so many of our friends and others throughout the world," said Redman, a three-time U.S. F5000 champion (1974-76), and the 1981 IMSA Camel GT champion, who is coordinating the fund-raising effort. "This is a great opportunity for many of us in the racing community to give back and help support a great cause."
The funds raised will benefit HD research by the Department of Neurology, David Geffen School of Medicine at UCLA. Huntington's is an inherited and fatal degenerative disease that progressively robs patients of the ability to think, judge appropriately, control their emotions and perform coordinated tasks.
The proceeds will also benefit the Huntington Disease Society of America's mission to improve the lives of people affected by HD and their families by supporting the UCLA Center of Excellence.
According to UCLA, it is an exciting time in HD research, and UCLA Neurology is confident that many groundbreaking discoveries are within reach. The understanding of the brain processes that are affected by the mutant huntingtin protein has increased dramatically over the past decade, and UCLA specialists are now poised to begin treatments that may have a dramatic impact on delaying the onset and slowing the progression of this disease.
"We thank Historic Sportscar Racing, Brian Redman, and all of the participants in this event to raise awareness and support for HD research. We extend our deepest appreciation to John Paul Jr., for his tireless drive and passion to improve the lives of HD patients and move our research forward," said Susan Perlman, M.D., Director, UCLA Huntington's Disease Center and Clinical Professor, UCLA Department of Neurology.
The JLP HD1 encompasses all the great 935s that John Paul Jr. raced in the '80s and beyond. The eight-driver team will compete against sports racers from the '50s, '60s and '70s, as well as GTP/Group C cars of the '80s and later, including Courage, Pescarolo and the Audi R8.
"I'm proud and honored to compete in this 4-hour enduro on behalf of the UCLA Huntington's Disease Center," said Haywood, a two-time Sebring 12-Hour and five-time Daytona 24-hour champion. "John Paul Jr. was a great competitor whom I had the privilege of racing against in the early IMSA days, and giving back to help in the research to eliminate this disease is an important goal."
PRESS RELEASE From Mauro Borella:
Castell'Arquato Italy… The "Vernasca Silver Flag Concours
d'Elegance" during the weekend of June 28-30, JLP-4, entered
under the "Ecurie Tycoonaire" flag, has been one of the central
attractions at the "Vernasca Silver Flag" in Castell'Arquato
Italy. The "Vernasca Silver Flag" is a dynamic "Concours d'Elegance" for race cars, that two times a day were able to run on a closed road course that once was the site of a famous hill climb race. The format of the event is much similar to the "Festival of Speed" in Goodwood, with rare historic cars arriving from all over the world. Well apart from being surprisingly able to go up the hill without any particular problem despite the tight corners and the Daytona-geared gearbox with blocked differential, JLP-4 has been awarded by the famous British auction house Coys with the prestigious and much sought-after "Spirit of Motoring" trophy. JLP-4 also won the special prize offered by Porsche for the most prestigious racing Porsche present at the event, despite the participation of other important cars like 907, 906, a Porsche 934 and the formerly owned Steve McQueen's Porsche 908. During the event the car was displayed and a lot of people asked about the JLP-HD Foundation project.
3/2013 JLP-HD1 will make its public debut at the 12 Hours of Sebring this week along with the original JLP2 formerly driven by John Paul Jr. A group of supporters and friends of John Paul Jr have purchased a 935 and recreated the old JLP 935 racecar and plan to campaign it on the historic and vintage circuits to create awareness of Huntington's disease and help raise funds for. The JLP-HD1 will enter the competitive series at The Mitty at Road Atlanta in April.
Both cars can be seen at the Sebring Museum, and some autographed posters will be available.
JOHN PAUL JR. JLP-HD1 PORSCHE 935 TO BE UNVEILED MARCH 2
Car Will Promote Awareness, Research into Huntington’s Disease
Los Angeles, CA. - In his heyday, John Paul Jr. was among the nation’s top professional race car drivers. He won races in the IRL/CART, IMSA Camel GT, and SCCA series and even drove briefly in NASCAR.
He since has been trying to raise national awareness of the disease, a campaign that this year will get a boost from friends and supporters who will race a newly-restored Porsche designated the “JLP-HD1 Porsche 935” on the historic and vintage circuits.
The JLP-HD1 Porsche 935, which recognizes John Paul’s most successful cars (JLP-2, JLP-3, JLP-4) and his current quest to find a cure for Huntington’s Disease (HD) through the John Paul Jr. Fund, will be unveiled to the media at a 1 p.m. on March 2, 2013.
The car is expected to make its competitive debut at the 12 Hours of Sebring, March 13-17, and during the year will be driven by a host of celebrity drivers including Brian Redman, John Andretti, and Jim Pace.
John Paul Jr.’s early exit from the competitive arena actually began when he noticed that he no longer could properly control the movements of his hands and feet while driving.
Since HD is not as well-known as Alzheimer’s (AD) or Parkinson’s (PD), funding and research have lagged behind. However, while they are all different diseases, they share some pathological similarities. As a result, it is hoped that breakthroughs in the treatment of one disease may shed light on the others.
The JLP-HD1 that will promote John Paul Jr.’s cause is built on a chassis that attempted the 12 hours of Sebring six times, the Rolex 24 Hours of Daytona three times and the 6 Hours of Watkins Glen twice, but never finished on the podium.
While it may never achieve the collectability status of the cars John Paul Jr. previously drove, it hopefully will help underscore the reality that it is the people who made previous victories possible, and it will again be the people who make the difference in the battle against HD that lies ahead.
When she's not working on research for HD, Dyna Shirasaki is lead singer for the band
Thund Her Struck and Hammer of the Broads.
We hope to see them perform at a future fundraising event.
Developments (Click any title for link)
"Obtaining a clear picture of the proteins that interact with the Huntingtin protein will provide clues for the development of Huntington's disease therapies. In this study, William Yang and colleagues used affinity-purification mass spectrometry to identify 747 candidate proteins that are complexed with Huntingtin in both Huntington's disease and wildtype mouse brains. Using Weighted Gene Correlation Network Analysis, they unveil a network of Htt-interacting protein modules that provide insight into distinct aspects of Huntingtin biology."
For more details, see Shirasaki et al., Neuron 75(1), 2012.
ScienceDaily (Nov. 1, 2012) — There's new hope in the fight against Huntington's disease. A group of researchers that includes scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have designed a compound that suppresses symptoms of the devastating disease in mice.
The compound is a synthetic antioxidant that targets mitochondria, an organelle within cells that serves as a cell's power plant. Oxidative damage to mitochondria is implicated in many neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's............ (click title for more)